Agenus Inc.

Agenus Inc.

Agenus Inc.

Overview
Date Founded

1999

Headquarters

3 Forbes Road,Lexington, MA 02421-7305

Type of Company

Public

Employees (Worldwide)

359

Industries

Biotechnology
Medical Support Services
Pharmaceuticals

Company Description

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA.

Contact Data
Trying to get in touch with decision makers at Agenus Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chairman, Chief Executive Officer & Co-Founder

President & Chief Operating Officer

Secretary, Vice President & General Counsel

Chief Technology Officer

Chief Commercial Officer

Vice President, Finance & Principal Financial & Accounting Officer

Chief Business Officer

Chief Medical Officer

Chief Manufacturing Officer

Vice President, Head of Commercial

Board of Directors

Chairman, Chief Executive Officer & Co-Founder at Agenus Inc.

Chief Executive Officer & Director at MiMedx Group, Inc.

President & Chief Executive Officer at X-Vax Technology, Inc.

Former Managing Director of Global Equities at TIAA-CREF Investment Management LLC

President at Vencor Capital (Pty) Ltd.

Former President at NearEast Pharma

Chief Executive Officer at Avillion LLP

Paths to Agenus Inc.
Potential Connections via
Relationship Science
You
Agenus Inc.
Owners & Shareholders
Details Hidden

RTW Investments aims to generate attractive risk-adjusted returns through investments in securities, both equity and debt, long and short, of companies with a focus on the healthcare sector. The Funds will primarily invest in the equity and debt of public and private issuers globally, with a focus on the US and Europe. Derivatives are employed to improve payoff structures, as well as to construct hedges.

Details Hidden

OIM is a fundamental research driven manager that is exclusively focused on the global health care and bioscience industries. Their investment strategy is based primarily on a top-down approach of understanding how the healthcare industry is evolving, followed by a bottom-up analysis of which companies they believe will out-perform or underperform over time.

Details Hidden

Invus Public Equities Advisors makes majority investments in private, high growth companies. The firm also takes significant, long-term positions in public companies whose fundamentals and management they believe in. Invus focuses on investments in the stocks of small- to mid-cap companies that are trading below the firm's assessment of their intrinsic business value. The average holding period in their public equity portfolio is measured in years. Invus invests in a variety of industries, including but not limited to, consumer products and services, food, specialty retail, software, biotechnology, medical devices, healthcare products and professional services.

Recent Transactions
Details Hidden

Agenus Inc. raised money in a private placement transaction

Details Hidden

Agenus Inc. raised money in a private placement transaction

Details Hidden

Agenus Inc. raised money in a private placement transaction

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Auditor

Advised onAgenus Inc. issued USD Common Stock

Legal Advisor

Advised onAgenus Inc. issued USD Common Stock

Escrow Agent

Advised onAgenus Inc. issued USD Common Stock

Partner, Investment Banking Segment

Advised onAgenus Inc. issued USD Common Stock

Legal Advisor

Advised onAgenus Inc. issued USD Common Stock

Legal Advisor

Advised onAgenus Inc. purchases 4-Antibody AG

Advisors & Consultants
Legal Advisor

Partner, San Diego at Cooley LLP

Legal Advisor

Partner at Ropes & Gray LLP

Senior Advisor

Executive Vice President, Research & Development at MiMedx Group, Inc.

Clients

Cowen and Company offers comprehensive investment banking services, including equity and convertible debt financings, private placements of equity and debt, restricted security sales, mergers and acquisitions advisory services including strategic alliances and joint ventures. In addition, we offer our clients access to world-class research, as well as institutional sales and trading services. Drawing upon the depth of our research and industry knowledge, we specialize in the key areas of growth in our economy. Our industry sector expertise includes Health Care, Technology, Media & Telecommunications, Consumer, and Aerospace & Defense. In addition, we offer extensive and focused after market trading services as a leading market maker in our target sectors. While our principal product is knowledge, meeting the demands of our clients is our first order of business. We are convinced that the fundamental tenets that served us so well in the past century – uncompromising service, time-honored ethics, and a dedication to helping clients capitalize on change – will serve us well in this century.

Merck & Co., Inc., d.b.a. Merck Sharp & Dohme (MSD) outside the United States and Canada, is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. Merck & Co. was established as an American affiliate in 1891.

Since 1987, Gilead Sciences has worked to discover, develop and commercialize medications to advance the care of patients suffering from life-threatening diseases in areas of unmet medical need. In 25 years, Gilead has become a leading biopharmaceutical company with a portfolio of 15 marketed products, a growing pipeline of investigational drugs and approximately 5,000 employees in offices across four continents. Gilead's therapeutic areas of focus include HIV/AIDS, hepatitis, serious respiratory, cardiovascular, and metabolic conditions, cancer and inflammation

Key Stats and Financials As of 2020
Market Capitalization
$1.32B
Total Enterprise Value
$758M
Earnings Per Share
$-1.05
Revenue
$88.2M
Net Profit
$-181M
EBITDA
$-109M
Total Equity
$-185M
EBITDAMargin
-123.44%
Enterprise Value / Sales
8.6x
TEVNet Income
-4.19x
Debt TEV
0.38x
Total Debt
$290M
Three Year Compounded Annual Growth Rate Of Revenue
27.16%
Suppliers
Ludwig Institute for Cancer Research Biotechnology | New York, NY

Ludwig Institute For Cancer Research Ltd. is non-profit organization engages in the prevention and control of cancer through researches, integrated laboratory and clinical trials. The firm operates in the areas of cell biology, genomics, immunology, neuroscience, signaling, stem cells, therapeutic, tumor biology, brain and breast cancer, immunotherapy, and melanoma. The company was founded by Daniel K. Ludwig in 1971 and is headquartered in New York, NY.

University of Virginia Computer Software | Charlottesville, VA

The University of Virginia (often abbreviated as UVA, UVa, or Virginia) is a public research university in Charlottesville, Virginia, United States. It was conceived and designed by U.S. President Thomas Jefferson, and established in 1819. UVA's initial Board of Visitors included former Presidents of the United States Thomas Jefferson, James Madison, and James Monroe. Monroe owned the initial site of the University, which was mostly farmland. His law office and farmhouse are now the site of Brown College at Monroe Hill, a residential college at UVA. UVA is one of the eight original Public Ivy universities, and it is the only university campus in the United States that is designated a World Heritage Site by UNESCO. In the 2013 edition of U.S. News and World Report's National University Rankings, the school was listed as America's 2nd best public university; tied with UCLA and surpassed only by UC Berkeley.

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government. Johnson & Johnson is headquartered in New Brunswick, New Jersey, the consumer division being located in Skillman, New Jersey. The corporation includes some 250 subsidiary companies with operations in 60 countries and products sold in over 175 countries. Johnson & Johnson had worldwide sales of $82.6 billion during calendar year 2020. Johnson & Johnson's brands include numerous household names of medications and first aid supplies. Among its well-known consumer products are the Band-Aid Brand line of bandages, Tylenol medications, Johnson's Baby products, Neutrogena skin and beauty products, Clean & Clear facial wash and Acuvue contact lenses. Johnson & Johnson's pharmaceutical arm is Janssen Pharmaceutica.

Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Agenus Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Agenus Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Agenus Inc..